In the U.S. interest rate options market, trading aimed at the possibility of interest rate cuts in 2027 is on the rise. As the July indicators for prices, consumption, and employment have weakened, the short-term interest rate path is being re-priced. According to BlockBits, some investors are unwinding positions that bet on interest rate hikes in September and December, shifting to trades targeting the possibility of rate cuts before mid-2027. July's inflation and consumer demand have decreased, with non-farm employment dropping by 23,000 and retail sales experiencing the largest decline in over a year. This trend is contributing to a reduction in expectations for rate hikes ahead of the September Federal Open Market Committee (FOMC) meeting. In the SOFR options market, contracts aimed at a rate freeze in September and call option trades expiring in March and June 2027 have been confirmed. The market currently reflects about 9 basis points of potential rate increase for the September meeting, with cumulative tightening expectations estimated at around 40 basis points until June 2027. Prediction markets also show a 74-75% probability of a rate freeze by the Federal Reserve in September. It is noteworthy that high long-term Treasury yields are being maintained while bets on short-term rate cuts are emerging simultaneously. In the coming weeks, U.S. price indicators, employment market trends, and statements from Federal Reserve officials will remain key variables influencing market pricing.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.




Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.













Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.













Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.